NFKB1 and hepatocellular carcinoma: Thus, the latter can deliver circZFR to the recipient HCC cells, inhibit the STAT3/NF-κB signaling pathway, and facilitate HCC cells’ proliferation and chemoresistance to cisplatin [123].